Evidence that tirzepatide protects against diabetes-related cardiac damages
Pooled result · MACEResult — go to the resultHazard ratio 0.59 95% CI 0.40–0.79Authors' conclusion
Our findings indicate that TZT has beneficial effects on cardiac cells by positively modulating cardiomyocyte death, fibrosis, and hypertrophy in the presence of high glucose concentrations. This suggests that TZT may reduce the risk of diabetes-related cardiac damage, highlighting its potential as a therapeutic option for heart failure management clinical trials. Our study strongly supports the rationale behind the clinical trials currently underway, the results of which will be further investigated to gain insights into the cardiovascular safety and efficacy of TZT.
Study context
- Population
- Major randomised clinical trials of TZT (meta-analysis); human cardiac AC16 cells exposed to normal (5 mM) and high (33 mM) glucose for 7 days
- Comparison
- Tirzepatide vs control
- Outcome
- Major adverse cardiovascular events (MACE) occurrence (meta-analysis)
Methodological detailsthree-step approach, human cardiac AC16 cell line, bioinformatic interaction map
- Three-step approach
- Human cardiac AC16 cell line
- Bioinformatic interaction map
Pooled result
MACE
Hazard ratio
0.59
95% CI 0.40–0.79
As reported in the abstract
Further pooled results
Fibrosis, hypertrophy and cell-death markers in AC16 cells under high glucose · 7 days
- 100 nM TZT contrasted high glucose (HG)-induced increase in expression of markers of fibrosis, hypertrophy and cell death
- P < 0.05 for all investigated markers
Bioinformatics analysis
- Confirmed interaction between analysed markers and pathways by which TZT affects apoptosis, fibrosis and contractility
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →